Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Embolx

Embolx
2013 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Later Stage VC LATEST DEAL TYPE
$490K LATEST DEAL AMOUNT
10 INVESTORS
Description

Provider of balloon occlusion microcatheters designed to treat cancerous tumors, benign prostatic hyperplasia and uterine fibroids. The company's microcatheters sets a new standard for precise embolic delivery and superior target filling by controlling pressure to direct blood flow while protecting non-target surrounding tissues, enabling doctors to improve treatment for a variety of conditions and improves tumor kill by 41%.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Surgical Devices
Other Devices and Supplies
Primary Office
  • 530 Lakeside Drive
  • Suite 200
  • Sunnyvale, CA 94085
  • United States

+1 (408) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Embolx’s full profile, request a free trial.

Embolx Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 29-Jan-2019 $490K 000.00 Completed Generating Revenue
7. Early Stage VC 00.00 Completed Generating Revenue
6. Grant 06-Apr-2018 000 00.00 Completed Generating Revenue
5. Early Stage VC (Series B) 14-Dec-2017 00.00 00.00 000.00 Completed Generating Revenue
4. Early Stage VC (Series A2) 03-Mar-2016 00.00 00.000 0000 Completed Generating Revenue
3. Grant 01-Jan-2015 00000 00.000 Completed Generating Revenue
2. Angel (individual) 01-Dec-2014 $1.5M $1.75M 000 Completed Generating Revenue
1. Early Stage VC (Series A) 09-May-2014 $250K $250K Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Embolx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 000,000 00 000.00 000.00 00 000.00 00.000
Series A2 000,000 00 000.00 000.00 00 000.00 00.000
Series A1 404,836 8% $3.74 $3.74 1x $3.74 17.61%
Series A 151,874 8% $3.29 $3.29 1x $3.29 6.61%
To view this company’s complete Cap Table, request access »

Embolx Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
00000000 0000 0000 Venture Capital-Backed Westminster, CO 00 000.00 00000000000 000.00
To view this company’s complete list of competitors, request access »

Embolx Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
National Cancer Institute Government 000 0000 000000 0
Acorn Campus Ventures Venture Capital Minority 000 0000 000000 0
Sood Ventures Venture Capital Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
National Science Foundation Government 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Embolx Executive Team (6)

Name Title Board
Seat
Contact
Info
Michael Allen Chief Executive Officer, President & Board Member
Greg Halstead Director, Engineering & Operations
Michael Lin Director, Finance
John Layton Director, Marketing
Ben Felipe Director of Sales

1 Former Executive

You’re viewing 5 of 6 executives. Get the full list »

Embolx Board Members (5)

Name Representing Role Since Contact
Info
Frank Grillo Self Board Member & Secretary 000 0000
Michael Allen Embolx Chief Executive Officer, President & Board Member 000 0000
Norm Gitis Ph.D Band of Angels Chairman 000 0000
Paul Rogan Self Board Member 000 0000
Tianhong Xu Ph.D Self Board Member 000 0000